VFF

Business Context and Reporting Period

Company: Village Farms International, Inc. (VFF)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended September 30, 2024
Business Overview: VFF operates four segments: Produce (VF Fresh), Canadian Cannabis (Pure Sunfarms and Rose LifeScience), U.S. Cannabis (Balanced Health), and Clean Energy (VF Clean Energy). The company is a non-accelerated filer and a smaller reporting company.

Key Financial Metrics

Note: Total Debt includes Line of Credit ($4,000), Current Maturities ($8,649), and Long-term Debt ($34,604).

Material Changes vs. Prior Period

• Revenue Growth: Sales increased 20% year-over-year (YoY) for both Q3 and the nine-month period, driven by a 27% increase in Canadian Cannabis sales and a 20% increase in Produce sales. U.S. Cannabis sales declined 21% in Q3 due to regulatory restrictions and market competition.
• Impairment Charges: The nine-month 2024 net loss was significantly impacted by a non-cash goodwill and intangible asset impairment of $11,939 in the U.S. Cannabis segment. This charge was not present in the prior year period.
• Profitability: While Q3 net loss narrowed to $(820) from $(1,299) in Q3 2023, the nine-month loss widened to $(27,221) from $(9,315) primarily due to the impairment charge and higher SG&A expenses.
• Segment Performance:
  • Canadian Cannabis: Maintained strong market share (No. 2 nationally) with increased volume in branded and non-branded sales. Gross margin decreased to 26% (from 35% in Q3 2023) due to product mix shifts.
  • Produce (VF Fresh): Improved gross margin to 8% in Q3 (from 4% in Q3 2023) due to lower cost per pound and increased yields.
  • U.S. Cannabis: Sales declined due to new CBD restrictions in eight states and proliferation of unregulated hemp products.

Guidance, Outlook, Risks, and Unusual Items

• Outlook & Developments:
  • Netherlands Expansion: Cultivation began in October 2024 at the Leli Holland facility; first sales expected in Q1 2025.
  • U.S. Regulatory: The company is a participant in the DEA's Administrative Law Judge hearing regarding marijuana rescheduling (expected Jan/Feb 2025). A Texas medicinal marijuana license application remains pending.
  • Energy: The Delta RNG Project commenced operations in April 2024, contributing incremental profit.
• Risks & Contingencies:
  • Nasdaq Compliance: The company received notification of non-compliance with the minimum bid price requirement ($1.00). It has until April 16, 2025, to regain compliance.
  • Internal Controls: Management identified a material weakness in IT general controls (user access and program change management) for the Produce segment. Disclosure controls and procedures are deemed ineffective as of September 30, 2024.
  • Regulatory: Ongoing uncertainty regarding U.S. federal cannabis laws and state-level CBD restrictions.
• Unusual Items:
  • Accounting Revision: An immaterial misstatement regarding deferred tax asset valuation allowance was corrected, reducing retained earnings by $3,000 as of December 31, 2023.
  • Acquisitions: Acquired remaining 15% of Leli (100% ownership) and additional 10% of Rose LifeScience (80% ownership) during the period.

Investor Verification Checklist

• Impairment Validity: Verify the assumptions used for the $11.9M U.S. Cannabis impairment (discount rates, growth forecasts) given the volatile CBD market.
• Nasdaq Compliance Plan: Monitor the company's strategy to regain compliance with the $1.00 minimum bid price requirement by April 2025.
• Internal Control Remediation: Track progress on remediation of the material weakness in IT general controls for the Produce segment.
• Debt Covenants: Confirm continued compliance with financial covenants, particularly the FCC Term Loan, which requires annual testing (next date: Dec 31, 2024).
• U.S. Cannabis Viability: Assess the impact of state-level CBD restrictions and the potential timeline for federal rescheduling on the Balanced Health segment.